Gilead Joins Forces with Global Drugmakers to Expand Access to Generic HIV Treatment in Low-Income Countries

Gilead Sciences Inc. has made a strategic move to tackle the HIV pandemic by announcing an initiative to partner with six drug manufacturers to produce generic versions of lenacapavir. This initiative will target 120 lower-income countries, aiming to enhance access to critical HIV treatment. While this development has been welcomed as a positive stride towards combating the HIV crisis, advocacy groups are calling on Gilead to broaden the scope of its plan to include additional countries and populations in need. Further details can be accessed in the report on the initiative.